Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
|Articles|March 4, 2014
ASCO grant open to OD students and residents
The Association of School and Colleges of Optometry is accepting applications from optometry students from accredited optometry schools and colleges in the United States and Puerto Rico and optometry residents for its Cultural Competency Case Study Competition for Students and Residents.
Advertisement
Rockville, MD-The
Submissions will be accepted through April 14, 2014. ASCO will award $2,500 to one optometry students and $2,500 to one optometry resident.
Applicants are strongly encouraged to view ASCO’s
Advertisement
Related to this article
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
Study: OCTA analysis tools report different macular vessel density values for glaucoma
3
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5